Patient Demographics
| Patient no. | Site of disease | Time from original diagnosis (y) | Primary removed | No. of previous chemotherapy regimes | Previous endocrine treatment | Histology |
|---|---|---|---|---|---|---|
| 1 | SCF | 7 | Y | 5 | Y | Grade 2 IDC, ER 210/300, PR 60/300, cerbB2 −ve |
| 2 | Breast, bone | 1 | N | 0 | Y | Grade 2 IDC, ER 300/300, PR 120/300, cerbB2 −ve |
| 3 | Liver, bone | 2 | Y | 2 | Y | Grade 2 IDC, ER 300/300, PR 300/300, cerbB2 −ve |
| 4 | Liver | 8 | Y | 1 | Y | Grade 2 IDC, ER 300/300, PR 210/300, cerbB2 −ve |
| 5 | Lung | 2 | Y | 4 | N | Grade 3 IDC, ER −ve, PR −ve, cerbB2 −ve |
| 6 | Pleura, lung, lymph nodes | 9 | Y | 2 | Y | Grade 2 IDC, ER 210/300, PR −ve, cerbB2 −ve |
| 7 | Liver, pleural fluid | 8 | Y | 1 | Y | Grade 2 IDC, ER 220/300, PR 60/300, cerbB2 −ve |
IDC = invasive ductal carcinoma; ER = estrogen receptor; PR = progesterone receptor; −ve = negative.